A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
The purpose of this study is to compare the efficacy and safety of ramosetron plus
 dexamethasone injection with granisetron plus dexamethasone injection for the prevention of
 chemotherapy-induced vomiting and nausea.
Inclusion Criteria:

 -  Subject with age between 20-74 years old (inclusive) of either sex

 -  Cancer subject is scheduled to receive the designated chemotherapy programs

 -  Subject without symptoms of vomiting for at least one week before dosing trial
 medication

 -  Subject with ECOG performance status scale no greater than 2

 -  Subject has signed the written informed consent form

 Exclusion Criteria:

 -  Subject has received radiotherapy to the abdomen or pelvis within 4 weeks before
 entering this study

 -  Subject has received the designated chemotherapy programs within 6 months before
 entering the study

 -  Subject has known heart failure or myocardial infraction or with laboratory
 abnormalities at screening

 -  Subject has known concurrent diseases that may cause vomiting

 -  Subject has taken medications that could influence the outcome of the study within 3
 days before entering the study

 -  Subject with a history of allergy or intolerance to ramosetron, granisetron or
 dexamethasone

 -  Female subject who is pregnant or breastfeeding

 -  Subject with life expectancy less than 3 months

 -  Subject participated other investigational drug trial within 1 month before entering
 this study